The current status of opioid maintenance treatment in France: a survey of physicians, patients, and out-of-treatment opioid users

References

• World Health OrganizationUnited Nations Office on Drugs and Crime; United Nations Programme on HIV/AIDS. WHO/UNODC/UNAIDS Position Paper: Substitution Maintenance Therapy in the Management of Opioid Dependence and HIV/AIDS PreventionGenevaWorld Health Organization2004 Available from: http://www.who.int/substance_abuse/activities/treatment_opioid_dependence/enAccessed May 9, 2014
   Google Scholar
• Year of introduction of methadone maintenance treatment, high-dosage buprenorphine treatment, buprenorphine/naloxone combination, heroin-assisted treatment and slow-release morphine [webpage on the Internet]LisbonEuropean Monitoring Centre for Drugs and Drug Addiction2012 Available from: http://www.emcdda.europa.eu/stats12#display:/stats12/hsrtab1Accessed May 9, 2014
   Google Scholar
• Drug treatment overview for France [webpage on the Internet]LisbonEuropean Monitoring Centre for Drugs and Drug Addiction2013 Available from: http://www.emcdda.europa.eu/data/treatment-overviews/FranceAccessed May 9, 2014
   Google Scholar
• Circulaire DGS/DHOS n° 2002-57 du 30 janvier 2002 relative à la prescription de la méthadone par les médecins exerçant en établissement de santé, dans le cadre de l’initialisation d’un traitement de substitution pour les toxicomanes dépendants majeurs aux opiacés [DGC/DHOS Circular n° 2000–57, January 30, 2002 relative to methadone prescription by physicians who practice within health institutions, within the framework of initiating substitution treatment in patients with major opiate dependence] [webpage on the Internet]FranceBureau SD 6 B2002 Available from: http://www.sante.gouv.fr/fichiers/bo/2002/02-08/a0080670.htmAccessed January 19, 2014 French
   Google Scholar
• FatseasMAuriacombeMWhy buprenorphine is so successful in treating opiate addiction in FranceCurr Psychiatry Rep20079535836417915074
   PubMedGoogle Scholar
• National drug strategies France [webpage on the Internet]LisbonEuropean Monitoring Centre for Drugs and Drug Addiction2012 Available from: http://www.emcdda.europa.eu/countries/national-drug-strategies/franceAccessed May 9, 2014
   Google Scholar
• DuburcqACharpakYBlinPMadecLTwo years follow-up of a heroin users cohort treated with high dosage buprenorphine. Results of the SPESUB study (pharmacoepidemiologic follow-up of general practice Subutex)Rev Epidemiol Sante Publique2000484363373 French [with English abstract]11011303
   PubMed Web of Science ®Google Scholar
• De DuclaMGagnonAMucchielliARobinetSVellayAComparison of high dose buprenorphine treatments of opiate dependent outpatients in four healthcare networksAnn Med Interne (Paris)2000151Suppl BB9B1511104938
   PubMedGoogle Scholar
• FhimaAHenrionRLowensteinWCharpakYTwo-year follow-up of an opioid-user cohort treated with high-dose buprenorphine (Subutex)Ann Med Interne (Paris)2001152Suppl 3IS26IS36 French [with English abstract]11435992
   PubMedGoogle Scholar
• EmmanuelliJDesenclosJCHarm reduction interventions, behaviours and associated health outcomes in France, 1996–2003Addiction2005100111690170016277629
   PubMed Web of Science ®Google Scholar
• RouxPVillesVBryDBuprenorphine sniffing as a response to inadequate care in substituted patients: results from the Subazur survey in south-eastern FranceAddict Behav200833121625162918775604
   PubMed Web of Science ®Google Scholar
• Vidal-TrecanGVaresconINabetNBoissonnasAIntravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in FranceDrug Alcohol Depend200369217518112609698
   PubMed Web of Science ®Google Scholar
• PaulyVPradelVPourcelLEstimated magnitude of diversion and abuse of opioids relative to benzodiazepines in FranceDrug Alcohol Depend20121261–2132022475815
   PubMed Web of Science ®Google Scholar
• PradelVFraugerEThirionXImpact of a prescription monitoring program on doctor-shopping for high dosage buprenorphinePharmacoepidemiol Drug Saf2009181364319040199
   PubMed Web of Science ®Google Scholar
• FischerBBibbyMBouchardMThe global diversion of pharmaceutical drugsnon-medical use and diversion of psychotropic prescription drugs in North America: a review of sourcing routes and control measuresAddiction2010105122062207020840172
   PubMed Web of Science ®Google Scholar
• PaulyVFraugerEPradelVWhich indicators can public health authorities use to monitor prescription drug abuse and evaluate the impact of regulatory measures? Controlling high dosage buprenorphine abuseDrug Alcohol Depend20111131293620692778
   PubMed Web of Science ®Google Scholar
• OrmanJSKeatingGMBuprenorphine/naloxone: a review of its use in the treatment of opioid dependenceDrugs200969557760719368419
   PubMed Web of Science ®Google Scholar
• FischerGStöverHAssessing the current state of opioid-dependence treatment across Europe: methodology of the European Quality Audit of Opioid Treatment (EQUATOR) projectHeroin Addict Relat Clin Probl2012143570
   Web of Science ®Google Scholar
• StöverHAssessing the current state of public-health-related outcomes in opioid dependence across Europe: data from the EQUATOR analysisHeroin Addict Relat Clin Probl20121445164
   Web of Science ®Google Scholar
• StöverHBarriers to opioid substitution treatment access, entry and retention: a survey of opioid users, patients in treatment, and treating and non-treating physiciansEur Addict Res2011171445420975276
   PubMed Web of Science ®Google Scholar
• MaremmaniIForeword – EQUATOR publication seriesHeroin Addict Relat Clin Probl201214456
   Web of Science ®Google Scholar
• FischerGNavaFStöverHOutcomes of opioid-dependence treatment across Europe: identifying opportunities for improvementHeroin Addict Relat Clin Probl20121443950
   Google Scholar
• BellJShanahanMMutchCA randomized trial of effectiveness and cost-effectiveness of observed versus unobserved administration of buprenorphine-naloxone for heroin dependenceAddiction2007102121899190717784896
   PubMed Web of Science ®Google Scholar
• Dale-PereraAGoulaoJStöverHQuality of care provided to patients receiving Opioid Maintenance Treatment in Europe: Results from the EQUATOR analysisHeroin Addict Relat Clin Probl20121442338
   Web of Science ®Google Scholar
• AlhoHSinclairDVuoriEHolopainenAAbuse liability of buprenorphine-naloxone tablets in untreated IV drug usersDrug Alcohol Depend2007881757817055191
   PubMed Web of Science ®Google Scholar
• LaranceBDegenhardtLLintzerisNPost-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosingDrug Alcohol Depend20111182–326527321565452
   PubMed Web of Science ®Google Scholar
• FeroniIPeretti-WatelPMasutACoudertCParaponarisAObadiaYFrench general practitioners’ prescribing high-dosage buprenorphine maintenance treatment: is the existing training (good) enough?Addict Behav200530118719115561460
   PubMed Web of Science ®Google Scholar
• BachaJReastSPearlstoneATreatment practices and perceived challenges for European physicians treating opioid dependenceHeroin Addict Relat Clin Probl20101123919
   Google Scholar
• EMCDDA mission [webpage on the Internet]LisbonEuropean Monitoring Centre for Drugs and Drug Addiction2010 Available from: http://www.emcdda.europa.eu/about/missionAccessed May 9, 2014
   Google Scholar